Background
==========

Aberrant deregulation of some Receptor Tyrosine Kinases (RTKs) signalling underlies diverse facets of tumor pathobiology providing an attractive target for cancer therapy. Searching for novel cancer-associated RTKs is an important issue to discover new therapeutic opportunities. For this reason, we investigated the contribution of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) to human cancer.

Patients and methods
====================

The level of ROR1 protein expression, phosphorylation and cellular growth response to RNAi-mediated ROR1 knockdown was evaluated by an integrated screening in a panel of 43 cancer cell lines. ROR1 auto-kinase activity and transphosphorylation were determined by biochemical assays. Functional consequences of ROR1 silencing were evaluated by several *in vitro* and *in vivo* biological assays.

Results
=======

We demonstrated that although ROR1 is expressed in approximately 75% of the screened cancer cell lines, only gastric carcinoma cells (HS746T) and non-small cell lung carcinoma cells (NCI-H1993) exhibit high levels of ROR1 tyrosine phosphorylation and experience growth inhibition upon ROR1 suppression. Biochemical assays revealed that ROR1 is a pseudokinase lacking autocatalytic activity. Intriguingly, the two phospho-ROR1 positive cell lines both exhibited amplification and constitutive activation of the *MET* oncogene. ROR1 phosphorylation was abrogated by MET inhibition, indicating MET dependent transphosphorylation of ROR1. Silencing of ROR1 in HS746T and NCI-H1993 cells impaired cellular proliferation, growth and migration *in vitro* and induced a dramatic inhibition of tumorigenesis *in vivo*.

Conclusions
===========

Our data show that ROR1 is a pseudokinase functionally transphosphorylated by MET RTK, suggesting a critical role for ROR1 in malignant phenotypes sustained by the *MET* oncogene.
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